Following the registration of triclabendazole for human use and noting its use for public health purposes, the WHO Expert Committee on the Use of Essential Drugs recommended, at its December 1997 meeting, that the drug be put on the list of essential drugs.

In 1990, the World Health Organization's (WHO) Division of Control of Tropical Diseases (CTD) and the pharmaceutical company Ciba-Geigy concluded a Memorandum of Understanding to conduct additional clinical trials of triclabendazole in the treatment of fascioliasis and paragonimiasis.

According to a WHO sponsored independent review of all the data from the clinical trials, "the clinical studies conducted thus far indicate that triclabendazole is highly efficacious in treating human infections of